Press Releases

CRANBURY, N.J., May 2, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application […]

CRANBURY, N.J., March 19, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial

CRANBURY, N.J., March 15, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 25th Annual ROTH Conference on Monday, March 18, 2013, at 1:00 p.m. Pacific Time.  The conference will be held at the Ritz Carlton Laguna Niguel in Dana Point, CA. Carl Spana, Ph.D., President and Chief

CRANBURY, N.J., Feb. 14, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2012.  Palatin reported a net loss of $1.7 million, or $(0.02) per

CRANBURY, N.J., Feb. 8, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE-MKT: PTN) will announce its second quarter, fiscal year 2013 financial results on Thursday, February 14, 2013 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 14, 2013,

CRANBURY, N.J., Feb. 7, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 15th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 15th Annual BIO CEO & Investor Conference will take place February 11-12 at the Waldorf=Astoria in New York City. Carl

CRANBURY, N.J., Jan. 3, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced today it has received net proceeds of approximately $1.75 million of non-dilutive funding through the New Jersey Economic Development Authority’s tax credit transfer program.  Palatin Technologies sold both New Jersey net operating losses and research and development tax credits to unrelated corporations.

CRANBURY, N.J., Nov. 20, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 24th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2012 at 3:10 p.m. Eastern Time.  The conference will be held at The New York Plaza, New York. Carl Spana, Ph.D., President and Chief Executive

CRANBURY, N.J., Nov. 14, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2012.  Recent HighlightsOn July 3, 2012, Palatin closed on a private placement

CRANBURY, N.J., Nov. 12, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012, at 10:30 a.m. Eastern Time.  The conference will be held at The Pierre Hotel, New York City. Carl Spana, Ph.D., President and Chief